国产氨曲南治疗革兰氏阴性杆菌感染的临床评价

Clinical evaluation of domestic aztreonam on the treatment of Gramnegative bacterial infections

以国产氨曲南注射剂治疗革兰氏阴性杆菌所致呼吸道、泌尿道、腹腔、皮肤软组织感染和败血症等患者共７１例，评价该药的疗效和安全性。并以氨曲南进口品为对照药，在６４例呼吸道和尿路感染中进行随机对照研究。结果显示国产氨曲南治疗各类感染的总有效率为８８．７％，细菌清除率为８７％，不良反应发生率为２．１％。随机对照观察结果显示治疗组与对照组的有效率、细菌清除率、不良反应发生率相仿，两组差异无显著性。ＭＩＣ测定结果显示氨曲南对大肠杆菌、肺炎克雷伯氏菌等肠杆菌科细菌具高度抗菌活性，与第三代头孢菌素、阿米卡星和环丙沙星相仿，对大肠杆菌的活性明显高于环丙沙星。本研究结果显示国产氨曲南治疗革兰氏阴性杆菌感染疗效确切，不良反应少见而轻微，其疗效和安全性与进口品相仿。

To evaluate the efficacy and safety of domestic aztreonam on the treatment of Gramnegative bacterial infections, 71 cases of respiratory, urinary, intraabdominal, soft tissue & skin infections and septicemia were treated with domestic aztreonam, as well as a rendomized controlled study was carried out in 64 cases of respiratory and urinary tract infections with domestic aztreonam vs imported one. Total effective and bacterial eradication rates were 88.7% and 87% for domestic aztreonam respectively, adverse reaction occurred in 2.1% of patients. Results of the randomized controlled study showed that the effective, bacterial eradication and adverse reaction rates were comparable in two groups. Results of the MIC demonstrated that aztreonam was highly active against E.coli, K.pneumoniae and other Enterobacteriaceae, similar to those of the 3rd generation cephlosporins, amikacin and ciprofloxacin, and superior to that of ciprofloxacin for E.coli. Conclusion: domestic aztreonam is effective for the treatment of infections caused by Gramgegative bcateria and the adverse reaction of the drug is rare and mild. The efficacy and safety of the domestic aztreonam are similar to those of imported one.